{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:12:35Z","timestamp":1771355555846,"version":"3.50.1"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,1,15]]},"DOI":"10.2169\/internalmedicine.4286-19","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T22:05:35Z","timestamp":1584569135000},"page":"161-166","source":"Crossref","is-referenced-by-count":3,"title":["Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-"],"prefix":"10.2169","volume":"60","author":[{"given":"Akihide","family":"Konishi","sequence":"first","affiliation":[{"name":"Clinical & Translational Research Center, Kobe University Hospital, Japan"},{"name":"Pharmaceuticals and Medical Devices Agency, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Ho","sequence":"additional","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Mitsutake","sequence":"additional","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Shirato","sequence":"additional","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Toshiyuki H, Konomi I, Hisashi K, Noriatsu K. The current status of Sakigake Designation in Japan, PRIME in the European Union, and breakthrough therapy designation in the United States. Therapeutic Innovation & Regulatory Science 51: 51-54, 2017.","DOI":"10.1177\/2168479016662682"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McClellan MB, Sigal EV. The 21st Century Cures Act. N Engl J Med 373: 1677-1678, 2015.","DOI":"10.1056\/NEJMc1509640"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kesselheim AS, Avorn J. The 21st Century Cures Act. N Engl J Med 373: 1679-1680, 2015.","DOI":"10.1056\/NEJMc1509640"},{"key":"4","unstructured":"4. Konishi A, Isobe S, Sato D. New regulatory framework for medical devices in Japan: current regulatory considerations regarding clinical studies. J Vasc Interv Radiol 29: 657-660, 2018."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Konishi A, Ho M, Shirai Y, Shirato H. First approval of improved medical device conditional on use-result survey in Japan- regulatory review of polymer-free drug-coated bioFreedom coronary stent. Circ J 82: 1487-1490, 2018.","DOI":"10.1253\/circj.CJ-17-1425"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 3: 1190-1198, 2010.","DOI":"10.1016\/j.jcin.2010.07.016"},{"key":"7","unstructured":"7. Baron SJ, Lei Y, Chinnakondepalli K, et al. Economic outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents in patients undergoing percutaneous coronary intervention: 1-year results from the ABSORB III trial. JACC Cardiovasc Interv 10: 774-782, 2017."},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Onuma Y, Sotomi Y, Shiomi H, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention 12: 1090-1101, 2016.","DOI":"10.4244\/EIJY16M09_01"},{"key":"9","unstructured":"9. Pharmaceuticals and Medical Devices Agency. absorbable coronary scaffold, Absorb GT1 review report 2015 [in Japanese] [Internet]. [cited 2020 Feb 16]. Available from: http:\/\/www.pmda.go.jp\/medical_devices\/2016\/M20161129001\/340733000_22800BZX00406000_A100_3.pdf."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Aoki J, Kozuma K, Awata M, et al. Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V\/PROMUS) in Japan. Cardiovasc Interv Ther 34: 40-46, 2019.","DOI":"10.1007\/s12928-018-0515-z"},{"key":"11","unstructured":"11. Stone GW, Kimura T, Gao R, et al. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol 4: 1261-1269, 2019."},{"key":"12","unstructured":"12. Nakamura M, Suzuki N, Kozuma K. ABSORB GT1 Japan PMS: 1-year results from absorb GT1 bioresorbable vascular scaffold Japan post marketing surveillance using BVS-specific implant technique: oral session presented at: Japanese Association of Cardiovascular Intervention and Therapeutics; 2019; Nagoya, Japan."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Suzuki N, Kozuma K, Nakamura S, et al. Absorb GT1 bioresorbable vascular scaffold system- 1-year post-marketing surveillance in Japan. Circ J 83: 2460-2465, 2019.","DOI":"10.1253\/circj.CJ-19-0636"},{"key":"14","unstructured":"14. Kereiakes DJ, Ellis SG, Metzger C, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: The ABSORB III trial. J Am Coll Cardiol 70: 2852-2862, 2017."},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Ali ZA, Gao R, Kimura T, et al. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation 137: 464-479, 2018.","DOI":"10.1161\/CIRCULATIONAHA.117.031843"},{"key":"16","unstructured":"16. Yamaji K, Ueki Y, Souteyrand G, et al. Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST registry. J Am Coll Cardiol 70: 2330-2344, 2017."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sotomi Y, Suwannasom P, Tenekecioglu E, et al. Imaging assessment of bioresorbable vascular scaffolds. Cardiovasc Interv Ther 33: 11-22, 2018.","DOI":"10.1007\/s12928-017-0486-5"},{"key":"18","unstructured":"18. TCT 2018. Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials [Internet]. [cited 2020 Feb 16]. Available from: https:\/\/www.tctmd.com\/news\/even-psp-bioresorbable-scaffold-falls-short-absorb-compare-and-absorb-iv-trials."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Konishi A, Ho M, Ouchi T, Mitsutake Y, Shirato H. Regulatory approval review of transcatheter mitral valve repair - difference in the indication between the USA and Japan. J Cardiol 74: 13-18, 2019.","DOI":"10.1016\/j.jjcc.2019.03.013"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Konishi A, Sakushima K, Isobe S, Sato D. First approval of regenerative medical products under the PMD act in Japan. Cell Stem Cell 18: 434-435, 2016.","DOI":"10.1016\/j.stem.2016.03.011"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/2\/60_4286-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T03:46:45Z","timestamp":1610768805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/2\/60_4286-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4286-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}